Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile
- 1 August 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 33 (4) , 413-421
Abstract
Purpose of review: Magnetic resonance spectroscopy (MRS) may play a key role for the management of patients with glioma. We highlighted the utility of MRS in the noninvasive diagnosis of gliomas with mutations in isocitrate dehydrogenase (IDH) genes, by providing an overview of the neurochemical alterations observed in different glioma subtypes, as well as during treatment and progression, both in vivo and ex vivo. Recent findings: D-2-hydroxyglutarate (2HG) decrease during anticancer treatments was recently shown to be associated with altered levels of other metabolites, including lactate, glutamate and glutathione, suggesting that tumour treatment leads to a metabolic reprogramming beyond 2HG depletion. In combination with 2HG quantification, cystathionine and glycine seem to be the most promising candidates for higher specific identification of glioma subtypes and follow-up of disease progression and response to treatment. Summary: The implementation of advanced MRS methods in the routine clinical practice will allow the quantification of metabolites that are not detectable with conventional methods and may enable immediate, accurate diagnosis of gliomas, which is crucial for planning optimal therapeutic strategies and follow-up examinations. The role of different metabolites as predictors of patient outcome still needs to be elucidated.Keywords
This publication has 42 references indexed in Scilit:
- A comparative study of short‐ and long‐TE 1H MRS at 3 T for in vivo detection of 2‐hydroxyglutarate in brain tumorsNMR in Biomedicine, 2013
- The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular CompartmentalizationJournal of Biological Chemistry, 2013
- 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomasNature Medicine, 2012
- Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade GliomasScience Translational Medicine, 2012
- Detection of 2-Hydroxyglutarate in IDH -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance SpectroscopyScience Translational Medicine, 2012
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyJournal of Neuro-Oncology, 2011
- Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolomeProceedings of the National Academy of Sciences, 2011
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomasNeurology, 2010
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- Free amino acids and related substances in human glial tumours and in fetal brain: comparison with normal adult brainBrain Research, 1976